Clinical trials: Oxaliplatin
Pancreatic Adenocarcinoma
Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma
This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with…
- Trial name
- NCT01558869
- Testing
- Capecitabine, Oxaliplatin, Irinotecan
- Where
- Hong Kong
- Volunteers
- 37 people
- Sponsor
- The University of Hong Kong
Metastatic Colorectal Cancer
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an…
- Trial name
- AFEMA (NCT03279289)
- Testing
- Aflibercept, Irinotecan, folinic acid (dl racemic)
- Where
- Spain
- Volunteers
- 170 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Biliary Tract Carcinoma, Initially Unresectable
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Study design: Prospective, single-arm, single-center phase II clinical study; Primary endpoint: Conversion rate; Secondary endpoints: Safety, disease control rate, disease-free survival, and overall survival; Main characteristics…
- Trial name
- NCT04984980
- Testing
- Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Colorectal Cancer, Resistance
Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)
Cancer-derived inflammation attenuates the efficacy of adjuvant chemotherapy (CT) in postoperative or metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer, Resistance, Bevacizimab, Inflamation
- Trial name
- NCT07241403
- Where
- China
- Volunteers
- 698 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Advanced Cancers
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
The goal of this clinical research study is to find the highest tolerable dose of the combination of oxaliplatin and capecitabine with or without bevacizumab that can be given to patients with advanced cancer that has spread to…
- Trial name
- NCT01213238
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- MOONRAY-01 (NCT06586515)
- Testing
- LY3962673, Cetuximab, Gemcitabine
- Where
- 52 sites in United States, Canada and 7 more
- Volunteers
- 630 people
- Sponsor
- Eli Lilly and Company
Rectal Cancer, Locally Advanced
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
A Single-arm phase II trial evaluating induction chemotherapy with FOLFIRINOXm followed by short course radiotherapy (RT) in locally advanced rectal carcinoma
- Trial name
- NCT05868317
- Testing
- Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan), Radiotherapy
- Where
- Tunisia
- Volunteers
- 70 people
- Sponsor
- Salah Azaïz Cancer Institute
Metastatic Adenocarcinoma of the Pancreas
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
This study is to assess the anti-tumour activity, safety and tolerability of irinotecan liposome injection (S095013) in combination with oxaliplatin, 5-Fluorouracil (5-FU) and levoisomer form of leucovorin (LLV).
- Trial name
- NCT06225999
- Testing
- Irinotecan liposome injection (S095013), Oxaliplatin, LLV (levoisomer form of leucovorin)
- Where
- 14 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Institut de Recherches Internationales Servier
Metastatic Colorectal Cancer
Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
Colorectal Cancer ranks third among the most frequent malignancies representing a leading cause of cancer-related death worldwide.
- Trial name
- Bohème (NCT05412706)
- Testing
- Niraparib
- Sponsor
- Ospedale Policlinico San Martino
Cancer of Pancreas, Cancer of the Pancreas
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
The purpose of this study is to determine whether using FOLFIRINOX chemotherapy and Stereotactic Body Radiation Therapy (SBRT) prior to surgery in patients with pancreatic cancer is safe and well tolerated.
- Conditions
- Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer
- Trial name
- NCT01446458
- Testing
- Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Oesophago-gastric Cancer
REAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer
To determine whether adding panitumumab, an antibody against the epidermal growth factor receptor (EGFR), to standard chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX), improves the duration of survival of patients…
- Trial name
- REAL3 (NCT00824785)
- Testing
- epirubicin, oxaliplatin, capecitabine (EOX), EOX + panitumumab
- Where
- 7 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of capecitabine when given together with oxaliplatin, leucovorin calcium, and fluorouracil in treating patients with advanced cancer that is metastatic or cannot be…
- Trial name
- NCT00043121
- Testing
- oxaliplatin, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
This phase II study is a prospective, multi-center, double-blinded, and randomized trial to compare the efficacy and safety of perioperative SOX plus serplulimab with SOX plus placebo for locally advanced gastric adenocarcinoma…
- Conditions
- Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
- Trial name
- NCT05872685
- Testing
- S1, Oxaliplatin, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 314 people
- Sponsor
- Yu jiren
Non-Small Cell Lung Cancer
A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC
This is a Phase II, open-label, non-randomized study in patients with advanced non-squamous NSCLC. Each cycle will be 21 days. Patients will be evaluated every 2 cycles (~6 weeks) for response using RECIST criteria.
- Trial name
- NCT00251524
- Testing
- Bevacizumab, Oxaliplatin, Pemetrexed
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Veeda Oncology
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs at the time of day that allows for the best drug response may allow the doctor to give higher…
- Trial name
- NCT00039208
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- 20 sites in Belgium, France and 2 more
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Locally Advanced Colorectal Cancer
Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)
This study is designed to evaluate the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed or oxaliplatin versus no HIPEC in locally advanced colorectal cancer
- Trial name
- NCT02965248
- Testing
- Standard adjuvant systemic chemotherapy, Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed, Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and toripalimab in patients with advanced hepatocellular…
- Trial name
- NCT04044313
- Testing
- Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shi Ming
Biliary Tract Cancer
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
This Phase II clinical trial is to study the effectiveness and safety of continuous hepatic arterial infusion (HAI) of Oxaliplatin and Fluorouracil in Patients with Unresectable Biliary tract carcinomas, and to explore a better…
- Trial name
- NCT01572324
- Testing
- Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University
Gastric Cancer
Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma
It is a trial to compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus S-1 (SOX) as first-line treatment in advanced or recurrent gastric adenocarcinoma.
- Trial name
- NCT03801668
- Testing
- Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Huazhong University of Science and Technology
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
This phase II trial studies how well giving bevacizumab, radiation therapy, and combination chemotherapy works in treating patients who are undergoing surgery for locally advanced nonmetastatic rectal cancer.
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
- Trial name
- NCT00321685
- Testing
- Bevacizumab, Capecitabine, Fluorouracil
- Where
- 107 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)